Medscape is available in 5 Language Editions – Choose your Edition here.


Vasculitic Neuropathy Workup

  • Author: Abbas Mehdi, MD; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
Updated: Feb 05, 2015

Laboratory Studies

Laboratory studies are more helpful in systemic than nonsystemic vasculitis; however, obtain the following studies in any patient in whom vasculitic neuropathy is suspected. In general, place the results in the context of the clinical presentation for a diagnosis. For those individuals with multiple high levels of the inflammatory markers listed here, consultation with a rheumatologist is strongly recommended.

Nonsystemic vasculitic neuropathy has a better prognosis than systemic vasculitic neuropathy. The former may have normal laboratory results, while systemic vasculitis often features elevated antinuclear antibody (ANA) titers, erythrocyte sedimentation rate (ESR), and other more specific markers of disease.

  • ESR (high, after age adjusted) - More than 70% of patients show ESR >20 mm/h
  • Antinuclear antibody titer (high in systemic diseases associated with vasculitic neuropathy)
  • Extractable nuclear antigens, p-ANCA and c-ANCA
  • Rheumatoid factor
  • Antineutrophil cytoplasmic antibodies
  • Hepatic enzymes
  • Renal function tests
  • Serum complement
  • Serum immunoelectrophoresis (or immunofixation) and quantitative immunoglobulins
  • Cryoglobulins
  • Hepatitis B antigen and antibody
  • Hepatitis C antigen

Routine cell count and serum electrolytes are indicated. Anemia is present in up to 30% of patients.

Serum analysis for other common causes of neuropathy, including hemoglobin A1c (HbA1c) and fasting glucose to rule out diabetes, thyroid function tests, B-12 and folate, and rapid plasma reagent (RPR).

CSF analysis can show high protein levels (>50 mg) in a small percentage of patients.


Imaging Studies

Brain imaging studies are usually not necessary, and a central nervous system etiology can be excluded comfortably by an accurate neurologic examination.

Magnetic resonance imaging (MRI) of the spine can be helpful in excluding a spinal nerve root lesion when suggested.


Other Tests

Nerve conduction studies and electromyography

Electrodiagnostic testing is essential in making the diagnosis of any neuropathy, especially in vasculitic neuropathy. Electrodiagnostic testing can help accurately define the pathophysiology and localize the extent and distribution of the neuropathy. It also can provide information on whether the disease is active in the form of signs of active denervation, which accordingly facilitates choice of treatment protocol.

The predominant electrophysiologic feature of vasculitic mononeuropathy multiplex is axonal loss. "Conduction block" in vasculitic mononeuropathy multiplex is secondary to focal axonal conduction failure, presumably related to infarct of the axon.

Needle electromyography can demonstrate denervation potentials. Presence of positive sharp waves and fibrillation potentials indicates active denervation. Amplitude and duration of motor units assess the duration of axon loss and the presence of reinnervation changes. Recruitment pattern identifies the amount of functional axonal loss.



Nerve and muscle biopsy

Tissue diagnosis is the criterion standard in making the diagnosis of vasculitic neuropathy and is recommended in the presence of any doubtful clinical picture or if ultimate diagnosis is required.

Biopsy may not be necessary if the clinical presentation of multifocal neuropathy is confirmed by electrodiagnostic testing and other systemic signs of vasculitis are present. Many academic institutions perform biopsy initially.

Sural nerve, superficial peroneal nerve, and muscle tissues (peroneus brevis) are most suitable for biopsy.

Blood vessels are infiltrated by inflammatory cells with signs of vascular injury including endothelial cell disruption, fragmentation of the internal elastic lamina, and fibrinoid necrosis with hemorrhage or thrombus; these findings are seen in definitive cases of nerve biopsy.


Histologic Findings

The diagnosis of peripheral nerve involvement may be established by nerve and muscle biopsies; these tissues typically exhibit inflammatory cell infiltrates and fibrinoid necrosis of the walls of blood vessels. However, the biopsy specimen may demonstrate only axonal degeneration if vasculitis has caused a nerve infarct that is proximal to the site of biopsy or if no affected vessels are encountered in the specimen.

Immunohistochemical evaluation of sural nerve biopsy specimens may be helpful in identifying patients with microvasculitis.

Pathologic features associated with necrotizing vasculitis include muscle fiber necrosis and/or regeneration, predominant axonal nerve pathology, wallerian-like degeneration, and asymmetric nerve fiber loss.

Contributor Information and Disclosures

Abbas Mehdi, MD Director, MDA Center of Central California; Consulting Staff, Department of Neurology, California Neurological Center, Inc

Abbas Mehdi, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, American Medical Association

Disclosure: Nothing to disclose.


Said R Beydoun, MD Chief, Professor, Department of Neurology, University Hospital, University of Southern California

Said R Beydoun, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Glenn Lopate, MD Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, Phi Beta Kappa

Disclosure: Nothing to disclose.

Chief Editor

Nicholas Lorenzo, MD, MHA, CPE Founding Editor-in-Chief, eMedicine Neurology; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American Academy of Neurology

Disclosure: Nothing to disclose.

Additional Contributors

Norman C Reynolds, Jr, MD Neurologist, Veterans Affairs Medical Center of Milwaukee; Clinical Professor, Medical College of Wisconsin

Norman C Reynolds, Jr, MD is a member of the following medical societies: American Academy of Neurology, Association of Military Surgeons of the US, International Parkinson and Movement Disorder Society, Sigma Xi, Society for Neuroscience

Disclosure: Nothing to disclose.

  1. Kernohan JW, Woltman HW. Periarteritis nodosa: a clinicopathologic study with special reference to the nervous system. Arch Neurol Psychiatry. 1938. 39:655-86.

  2. Dyck PJ, Benstead TJ, Conn DL, et al. Nonsystemic vasculitic neuropathy. Brain. 1987 Aug. 110 ( Pt 4):843-53. [Medline].

  3. Davies L, Spies JM, Pollard JD, McLeod JG. Vasculitis confined to peripheral nerves. Brain. 1996 Oct. 119 ( Pt 5):1441-8. [Medline].

  4. Kissel JT, Riethman JL, Omerza J, Rammohan KW, Mendell JR. Peripheral nerve vasculitis: immune characterization of the vascular lesions. Ann Neurol. 1989 Mar. 25(3):291-7. [Medline].

  5. Murthy JM, Sundaram C, Meena AK. Nonsystemic vasculitic neuropathy. J Assoc Physicians India. 1998 Feb. 46(2):204-6. [Medline].

  6. Larrode P, Ramon y Cajal S, Iníguez C, Dominguez M, Sanz JM, Morales F. [Isolated vasculitis of the peripheral nervous system]. Neurologia. 1997 May. 12(5):197-9. [Medline].

  7. Collins MP, Mendell JR, Periquet MI, Sahenk Z, Amato AA, Gronseth GS. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology. 2000 Sep 12. 55(5):636-43. [Medline].

  8. Sanchez GM, Villanueva-Haba VE, Sevilla Mantecon T, Mayordomo Fenandez F, Vilchez Padilla JJ. Nonsystemic vasculitic neuropathy. Neurologia. 2002. 17:613-5.

  9. Vrancken AF, Said G. Vasculitic neuropathy. Handb Clin Neurol. 2013. 115:463-83. [Medline].

  10. Gwathmey KG, Burns TM, Collins MP, Dyck PJ. Vasculitic neuropathies. Lancet Neurol. 2014 Jan. 13(1):67-82. [Medline].

  11. Collins MP, Periquet MI, Mendell JR, Sahenk Z, Nagaraja HN, Kissel JT. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology. 2003 Sep 9. 61(5):623-30. [Medline].

  12. Mathew L, Talbot K, Love S, Puvanarajah S, Donaghy M. Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome. QJM. 2007 Jan. 100(1):41-51. [Medline].

  13. Kissel JT, Slivka AP, Warmolts JR, Mendell JR. The clinical spectrum of necrotizing angiopathy of the peripheral nervous system. Ann Neurol. 1985 Aug. 18(2):251-7. [Medline].

  14. Kararizou E, Davaki P, Karandreas N, Davou R, Vassilopoulos D. Nonsystemic vasculitic neuropathy: a clinicopathological study of 22 cases. J Rheumatol. 2005 May. 32(5):853-8. [Medline].

  15. Jayne D. Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford). 2000 Jun. 39(6):585-95. [Medline].

  16. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb. 37(2):187-92. [Medline].

  17. Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med. 1967 Jul. 43(1):8-14. [Medline].

  18. Moore PM, Cupps TR. Neurological complications of vasculitis. Ann Neurol. 1983 Aug. 14(2):155-67. [Medline].

  19. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999 Jan. 78(1):26-37. [Medline].

  20. Sehgal M, Swanson JW, DeRemee RA, Colby TV. Neurologic manifestations of Churg-Strauss syndrome. Mayo Clin Proc. 1995 Apr. 70(4):337-41. [Medline].

  21. Hirahara T, Yamashita S, Misumi Y, Kawakami K, Hori H, Honda S, et al. Gait disturbance due to foot drop is refractory to treatment in nonsystemic vasculitic neuropathy. Eur Neurol. 2014. 71(3-4):180-6. [Medline].

  22. Abgrall S, Mouthon L, Cohen P, et al. Localized neurological necrotizing vasculitides. Three cases with isolated mononeuritis multiplex. J Rheumatol. 2001 Mar. 28(3):631-3. [Medline].

  23. Hawke SH, Davies L, Pamphlett R, et al. Vasculitic neuropathy. A clinical and pathological study. Brain. 1991 Oct. 114 ( Pt 5):2175-90. [Medline].

  24. Johnson R, Griffin J. Current Therapy in Neurologic Disease. 5th ed. Philadelphia: BC Decker;. 1997.

  25. Kissel JT, Mendell JR. Vasculitic neuropathy. Neurol Clin. 1992 Aug. 10(3):761-81. [Medline].

  26. Olney RK. Neuropathies associated with connective tissue disease. Semin Neurol. 1998. 18(1):63-72. [Medline].

  27. Said G. Vasculitic neuropathy. Curr Opin Neurol. 1999 Oct. 12(5):627-9. [Medline].

  28. Satoi H, Oka N, Kawasaki T, et al. Mechanisms of tissue injury in vasculitic neuropathies. Neurology. 1998 Feb. 50(2):492-6. [Medline].

  29. Vedeler CA. Inflammatory neuropathies: update. Curr Opin Neurol. 2000 Jun. 13(3):305-9. [Medline].

Diagnostic classification of peripheral vasculitic neuropathy (PVN).
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.